Home / Research

Who Can Participate?

  • 18 years of age or older
  • Able to read and write in English
  • Currently experiencing one or more of the following symptoms due to an acute illness: Fever or Chills, Cough, Fatigue, Muscle or Body Aches, Headache, Sore throat, Congestion or Runny Nose, Nausea or Vomiting, Diarrhea
  • Currently using cannabis products – Group 1
  • Not currently using cannabis products – Group 2
  • Must have smart phone or email and access to internet
  • Be able to comply with study requirements including baseline tele-health visit, completion of electronic questionnaires, and study timeline parameters

How To Enroll?

To enroll in this study, simply follow the steps below and complete the questionnaire.
Call 717-799-3270 or email [email protected]
Staff member will respond with information to complete questionnaire required for enrollment. Follow instructions provided by staff, trial medication will be provided by research team.

 

AGRI-KIND's Research Based Goals

  • Build our research off of the 30+ years of research performed on various Cannabinoids and Terpenes to date in Israel, the UK, Canada, and more recently in the United States.
  • Expand on the 25+ years of academic & NIMH Studies on the Endocannabinoid System coupled with the research of our partners, who are researching enhancements of pharmacokinetics or metabolism and body usage of scoped compounds from the cannabis plant.
  • Leverage our proprietary drug development technology platform to select key compounds by known effects and chemical structure to derive optimal formulations targeted at key conditions.
  • Utilize our proprietary patient care and outcomes platform to best analyze, document and continually improve product efficacy, dosage management, and overall patient care including the reduction of side effects and interactions.
  • Stay ahead of the curve in innovation over current, natural products available today and those currently under FDA clinical trials, forging new paths in the non-synthetic space.
  • Evolve the patient care aspects of the organization to include care centers and application of pharmacogenomics as we study relationships of known and new biomarkers that align with the cannabinoid receptors and various ailments.